Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression.… Read more
Alaunos Therapeutics Inc (TCRT) - Net Assets
Latest net assets as of September 2025: $2.80 Million USD
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has net assets worth $2.80 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.72 Million) and total liabilities ($921.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.80 Million |
| % of Total Assets | 75.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -98.34% |
| 10-Year Change | -97.64% |
| Growth Volatility | 125.49 |
Alaunos Therapeutics Inc - Net Assets Trend (2001–2024)
This chart illustrates how Alaunos Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alaunos Therapeutics Inc (2001–2024)
The table below shows the annual net assets of Alaunos Therapeutics Inc from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.06 Million | -67.29% |
| 2023-12-31 | $6.31 Million | -83.64% |
| 2022-12-31 | $38.55 Million | -33.59% |
| 2021-12-31 | $58.06 Million | -53.17% |
| 2020-12-31 | $123.98 Million | +30.49% |
| 2019-12-31 | $95.01 Million | +11.04% |
| 2018-12-31 | $85.56 Million | +188.39% |
| 2017-12-31 | $-96.81 Million | -25.24% |
| 2016-12-31 | $-77.30 Million | -188.47% |
| 2015-12-31 | $87.37 Million | +158.18% |
| 2014-12-31 | $33.84 Million | -31.47% |
| 2013-12-31 | $49.38 Million | +1.94% |
| 2012-12-31 | $48.45 Million | -32.35% |
| 2011-12-31 | $71.61 Million | +134.37% |
| 2010-12-31 | $30.55 Million | +8.71% |
| 2009-12-31 | $28.10 Million | +317.04% |
| 2008-12-31 | $6.74 Million | -77.81% |
| 2007-12-31 | $30.37 Million | +14.46% |
| 2006-12-31 | $26.53 Million | +268.42% |
| 2005-12-31 | $7.20 Million | +34354.11% |
| 2004-12-31 | $-21.02K | +18.15% |
| 2003-12-31 | $-25.69K | -48.18% |
| 2002-12-31 | $-17.33K | -562.87% |
| 2001-12-31 | $-2.62K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alaunos Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 92027546600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.10% |
| Other Components | $922.51 Million | 44716.77% |
| Total Equity | $2.06 Million | 100.00% |
Alaunos Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Alaunos Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cemat A/S
CO:CEMAT
|
$5.43 Million |
|
Sundaram Multi Pap Limited
NSE:SUNDARAM
|
$5.43 Million |
|
PT Superior Prima Sukses Tbk
JK:BLES
|
$5.43 Million |
|
Sarytogan Graphite Ltd
AU:SGA
|
$5.43 Million |
|
Sienna Resources Inc
PINK:SNNAF
|
$5.43 Million |
|
Bulletin Resources Limited
F:7BR
|
$5.43 Million |
|
PT Agung Menjangan Mas Tbk
JK:AMMS
|
$5.42 Million |
|
Mountain Province Diamonds Inc
PINK:MPVDF
|
$5.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alaunos Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,307,000 to 2,063,000, a change of -4,244,000 (-67.3%).
- Net loss of 4,679,000 reduced equity.
- Other factors increased equity by 435,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.68 Million | -226.81% |
| Other Changes | $435.00K | +21.09% |
| Total Change | $- | -67.29% |
Book Value vs Market Value Analysis
This analysis compares Alaunos Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.42x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $-9.33 | $3.12 | x |
| 2002-12-31 | $-11.60 | $3.12 | x |
| 2003-12-31 | $-13.12 | $3.12 | x |
| 2004-12-31 | $-21.17 | $3.12 | x |
| 2005-12-31 | $198.90 | $3.12 | x |
| 2006-12-31 | $316.57 | $3.12 | x |
| 2007-12-31 | $241.90 | $3.12 | x |
| 2008-12-31 | $47.61 | $3.12 | x |
| 2009-12-31 | $182.43 | $3.12 | x |
| 2010-12-31 | $99.62 | $3.12 | x |
| 2011-12-31 | $162.73 | $3.12 | x |
| 2012-12-31 | $92.52 | $3.12 | x |
| 2013-12-31 | $86.19 | $3.12 | x |
| 2014-12-31 | $50.19 | $3.12 | x |
| 2015-12-31 | $104.50 | $3.12 | x |
| 2016-12-31 | $-88.92 | $3.12 | x |
| 2017-12-31 | $-106.04 | $3.12 | x |
| 2018-12-31 | $89.43 | $3.12 | x |
| 2019-12-31 | $84.85 | $3.12 | x |
| 2020-12-31 | $88.71 | $3.12 | x |
| 2021-12-31 | $40.62 | $3.12 | x |
| 2022-12-31 | $26.63 | $3.12 | x |
| 2023-12-31 | $3.94 | $3.12 | x |
| 2024-12-31 | $1.29 | $3.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alaunos Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -226.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -46790.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.34x
- Recent ROE (-226.81%) is below the historical average (-112.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 0.00% | -4202.49% | 0.60x | 0.00x | $-71.14K |
| 2002 | 0.00% | -1554.12% | 5.13x | 0.00x | $-38.21K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-33.27K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.06K |
| 2005 | -132.14% | 0.00% | 0.00x | 1.32x | $-10.24 Million |
| 2006 | -67.30% | 0.00% | 0.00x | 1.11x | $-20.51 Million |
| 2007 | -87.61% | 0.00% | 0.00x | 1.21x | $-29.65 Million |
| 2008 | -374.40% | 0.00% | 0.00x | 1.87x | $-25.90 Million |
| 2009 | -27.22% | 0.00% | 0.00x | 1.77x | $-10.46 Million |
| 2010 | -106.93% | 0.00% | 0.00x | 2.01x | $-35.73 Million |
| 2011 | -89.07% | -9561.92% | 0.01x | 1.51x | $-70.94 Million |
| 2012 | -198.44% | -12016.50% | 0.01x | 1.72x | $-100.98 Million |
| 2013 | -115.64% | -7138.38% | 0.01x | 1.45x | $-62.05 Million |
| 2014 | -93.91% | -2314.71% | 0.03x | 1.34x | $-35.17 Million |
| 2015 | -137.45% | -2772.11% | 0.03x | 1.76x | $-128.83 Million |
| 2016 | 0.00% | -2409.23% | 0.06x | 0.00x | $-157.57 Million |
| 2017 | 0.00% | -850.26% | 0.06x | 0.00x | $-44.64 Million |
| 2018 | -62.08% | -36381.51% | 0.00x | 1.11x | $-61.67 Million |
| 2019 | -123.98% | 0.00% | 0.00x | 1.15x | $-127.30 Million |
| 2020 | -63.60% | 0.00% | 0.00x | 1.18x | $-91.25 Million |
| 2021 | -135.64% | -19786.68% | 0.00x | 1.63x | $-84.56 Million |
| 2022 | -97.86% | -1291.24% | 0.04x | 1.68x | $-41.59 Million |
| 2023 | -557.16% | -702800.00% | 0.00x | 1.31x | $-35.77 Million |
| 2024 | -226.81% | -46790.00% | 0.00x | 1.34x | $-4.89 Million |
Industry Comparison
This section compares Alaunos Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alaunos Therapeutics Inc (TCRT) | $2.80 Million | 0.00% | 0.33x | $5.43 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |